Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Former CDRH Director Put Problem Solving Before Data Monitoring

This article was originally published in The Gray Sheet

Executive Summary

[Editor's Note: To mark the FDA centennial and the 30-year anniversary of the Medical Device Amendments to the Food, Drug & Cosmetic Act, "The Gray Sheet" is conducting a series of interviews looking back at the history of device regulation. Recently we sat down with John Villforth, who served as CDRH Director from 1982-1990.

You may also be interested in...



Retiring Rep. Dingell’s Health Policy Legacy Includes Fierce Oversight Of Device Center

A powerful former Chairman of the House Energy and Commerce Committee, Dingell has been not only a major player in the health care reform fight, but also a vigorous prober of FDA, launching investigations with lasting effects on the device center. The longest-serving member of the House announced his plans to retire at the end of this congressional term.

Retiring Rep. Dingell’s Health Policy Legacy Included Fierce Oversight Of Device Center

A powerful former Chairman of the House Energy and Commerce Committee, Dingell has not been only a major player in the health care reform fight, but also a vigorous prober of FDA, launching investigations with lasting effects on the device center. The longest-serving member of the House announced his plans to retire at the end of this congressional term.

Factoring In Human Factors: An Interview With Peter Carstensen

Human factors engineering has slowly but surely become an ingrained part of how FDA regulates the medical device industry, according to Peter "Pete" Carstensen, but to keep that a reality he says the agency needs to hire more people and reestablish its former human factors-focused team

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

MT023745

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel